Anal Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults with biopsy-confirmed anal canal or perianal squamous cell carcinoma, adenocarcinoma, or other histologies at any stage (T1–T4, N0–N3, M0–M1)

• Patients with HIV who have a CD4 count ≥200 cells/µL and are on stable antiretroviral therapy (ART); CRT is feasible with appropriate haematological monitoring

• Patients with resectable or potentially resectable residual/recurrent disease after primary CRT who are candidates for salvage APR

• Patients with oligometastatic disease being considered for systemic therapy combined with local ablative treatment (stereotactic body radiotherapy — SBRT — to liver or lung metastases)

• Patients seeking a second opinion on staging, treatment planning, or recurrence management

• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL:

• Pathology report (biopsy slides or paraffin blocks) with HPV status, p16 immunohistochemistry, and tumour histology

• Pelvic MRI with contrast (ideally 1.5T or 3T): essential for T-staging, sphincter involvement, and nodal assessment

• FDG-PET/CT scan (whole body): for nodal and distant metastasis evaluation; required for accurate IMRT target volume delineation

• CT chest/abdomen/pelvis with contrast (if PET-CT not available)

• Full blood count, renal function (eGFR ≥45 mL/min required for platinum-based regimens), liver function tests, serum albumin

• HIV serology, CD4 count, and HIV viral load (mandatory)

• HPV genotyping (16/18 preferred)

• Echocardiogram (ECHO) if baseline cardiac compromise suspected or prior cardiotoxic chemotherapy received

• Audiogram if cisplatin-based therapy is planned

• Pulmonary function tests (PFTs) if thoracic SBRT is considered

• CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:

• Active inflammatory bowel disease (Crohn's or ulcerative colitis) involving the anorectum: significantly increases CRT toxicity risk; requires specialist gastroenterology co-management

• Prior high-dose pelvic radiotherapy: limits re-irradiation capacity; salvage surgery may be the only curative option

• Severe uncontrolled immunosuppression (CD4 <100 cells/µL, uncontrolled HIV viral load): CRT must be deferred until immune reconstitution

• Active fistula or septic pelvic infection: requires surgical drainage/defunctioning colostomy before CRT can commence

• Pregnancy: CRT is absolutely contraindicated; surgical options with multidisciplinary counselling are considered on a case-by-case basis

• WHO/ECOG performance status ≥3 or severe baseline organ dysfunction may preclude aggressive curative-intent therapy

DEFINITIVE CONCURRENT CHEMORADIATION THERAPY (CRT) — STANDARD OF CARE:

For non-metastatic anal SCC (Stages I–III), definitive CRT is the primary curative strategy, sparing the anal sphincter and avoiding permanent colostomy in the majority of patients. The internationally validated regimen consists of:

• Radiation Therapy: External beam radiotherapy (EBRT) at 45–50.4 Gy to the pelvis and regional nodes, with a sequential or simultaneous integrated boost (SIB) to the primary tumour to a total dose of 54–59.4 Gy, delivered over approximately 28–33 fractions (5.5–6.5 weeks).

• Delivery Technology: All GAF Healthcare partner centres employ Intensity-Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) to achieve highly conformal dose distribution, reducing acute toxicity (proctitis, cystitis, dermatitis, small bowel toxicity) compared to older 3D-CRT techniques. Image-Guided Radiotherapy (IGRT) with daily cone-beam CT is standard.

• Chemotherapy Backbone (Concurrent): Mitomycin-C (MMC) 10–12 mg/m² IV bolus on Days 1 and 29 + 5-Fluorouracil (5-FU) 1000 mg/m²/day as a continuous 96-hour infusion on Days 1–4 and 29–32. Alternatively, oral capecitabine (825 mg/m² twice daily on radiation days) is used as an evidence-based, more convenient substitute for 5-FU (UKCCCR ACT II data).

SURGICAL APPROACHES:

• Local Excision (Wide Local Excision / WLE): Reserved for small (≤2 cm), superficial T1 N0 tumours that do not involve the sphincter. Achieves R0 margins with sphincter preservation; cure rates >90% for appropriately selected tumours. Performed under general or spinal anaesthesia with transanal access.

• Abdominoperineal Resection (APR): The definitive surgical procedure for CRT failure, residual disease at 26-week post-CRT assessment, or recurrent anal cancer. Involves en-bloc removal of the rectum, anus, levator ani muscles, and surrounding perineal tissue, with construction of a permanent end colostomy. Robotic-assisted APR (using da Vinci Surgical System) is available at select partner centres, offering superior perineal dissection with 3D visualisation, reduced blood loss, and improved autonomic nerve preservation compared to conventional open APR — particularly beneficial in the previously irradiated, scarred pelvis. Extralevator APR (ELAPE) is performed for locally advanced T3–T4 tumours to achieve wider circumferential resection margins and reduce the risk of intraoperative perforation.

• Defunctioning Loop Colostomy: A palliative or bridging procedure performed laparoscopically to relieve faecal obstruction caused by bulky tumours or to protect the perianal skin during CRT in patients with severe pre-existing anal pathology or fistulae. This is not a curative intervention.

• Pelvic Exenteration: For ultra-locally advanced tumours invading the bladder, urethra, or vagina; performed at high-volume pelvic oncology centres with multidisciplinary reconstructive teams.

SYSTEMIC THERAPY FOR METASTATIC / REFRACTORY DISEASE:

• First-line: Carboplatin (AUC 5) + Paclitaxel (80 mg/m² weekly or 175 mg/m² every 3 weeks); this combination demonstrated superiority over cisplatin/5-FU in the InterAACT randomised trial with improved tolerability.

• Immunotherapy: Pembrolizumab (200 mg IV every 3 weeks) is FDA- and EMA-approved for MSI-high or PD-L1 CPS ≥10 anal SCC in the second-line setting (KEYNOTE-158 data, ORR ~12–16% in unselected, higher in biomarker-selected). Nivolumab has shown similar activity. PDL1/MSI-H/TMB-H biomarker testing (next-generation sequencing — NGS panel) is strongly recommended at diagnosis for all metastatic cases.

• HER2-Directed Therapy: Trastuzumab-based regimens are under evaluation for HER2-amplified anal adenocarcinoma in clinical trials.

• SBRT / Ablation for Oligometastases: For patients with 1–3 liver or lung metastases and controlled primary disease, stereotactic body radiotherapy (SBRT) or radiofrequency ablation (RFA) may be offered with curative or progression-delay intent.

INDUCTION AND NEOADJUVANT STRATEGIES:

• Induction chemotherapy with carboplatin/paclitaxel × 2 cycles prior to CRT is under active investigation (CCTG CO.26-style protocols) for bulky T3–T4 or N3 disease to reduce tumour burden before definitive radiotherapy.

PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–2):

• Step 1: Submit all diagnostic records (biopsy pathology, MRI, PET-CT, blood results) to GAF Healthcare's oncology coordination team via the secure patient portal.

• Step 2: Virtual multidisciplinary tumour board review by the partner hospital team (medical oncologist, radiation oncologist, colorectal surgeon). A detailed treatment plan and cost estimate are issued within 48–72 hours.

• Step 3: GAF Healthcare assists with e-Medical Visa application (India) or coordinates entry visa requirements (UAE). Travel and accommodation arrangements for patient and one attendant are confirmed.

PHASE 2 — ARRIVAL & WORKUP (Days 1–5 in country):

• Step 4: Airport reception by GAF Healthcare's dedicated patient liaison officer. Transfer to pre-arranged hospital-adjacent accommodation or a private hospital room.

• Step 5: Repeat or complementary diagnostics as required: high-resolution anoscopy/EUA (examination under anaesthesia) for precise T-staging, fresh blood work, cardiac ECHO if indicated, nutritional assessment (serum albumin, BMI), and stomatology/dental review if head/neck radiation ports are involved.

• Step 6: Radiation Oncology simulation session: CT simulation scan in treatment position with customised immobilisation devices (vacuum-lock bag, knee rest); target volume delineation and IMRT/VMAT treatment plan optimisation (typically requires 3–5 business days of physics planning).

• Step 7: Medical oncology consultation to confirm chemotherapy regimen, ensure adequate renal/hepatic function, and insert a PICC line or portacath if continuous 5-FU infusion is planned.

PHASE 3 — ACTIVE TREATMENT (Weeks 2–8):

• Step 8: CRT commences. Radiation delivered Monday–Friday (5 days/week) over 5.5–6.5 weeks (28–33 fractions). Chemotherapy (MMC bolus on Days 1 and 29; 5-FU infusion on Days 1–4 and 29–32, or daily capecitabine) administered concurrently.

• Step 9: Weekly on-treatment reviews with radiation oncologist and medical oncologist to assess acute toxicity (skin desquamation, proctitis, cystitis, mucositis, haematological suppression), manage side effects (topical barrier creams, analgesia, anti-diarrhoeals, G-CSF if required), and perform treatment verification imaging.

• Step 10 (Surgical cases only): If proceeding to planned surgical resection (WLE or APR), hospitalisation is typically 7–14 days post-operatively. Stoma nurse education and psychological support for permanent colostomy patients are provided by specialist colorectal nursing teams.

PHASE 4 — POST-TREATMENT ASSESSMENT & RECOVERY (Weeks 8–14 in country):

• Step 11: Clinical response assessment at 8 weeks post-CRT: digital rectal examination, pelvic MRI, and PET-CT scan. Complete clinical response (cCR) in the primary tumour in approximately 60–70% of patients at this time point; definitive response assessment may continue up to 26 weeks (per ACT II protocol).

• Step 12: If cCR is confirmed, active surveillance commences. If residual disease is confirmed at 26 weeks, multidisciplinary discussion regarding salvage APR is initiated.

• Step 13: Fit-to-fly assessment. After CRT, most patients can safely travel internationally at 6–8 weeks post-treatment completion, provided acute toxicity has resolved (skin healing, haematological recovery to safe thresholds). After APR, minimum 4–6 weeks with wound healing and stoma stability confirmed.

• Step 14: Discharge summary, full imaging and pathology reports in English, and a detailed follow-up protocol (3-monthly clinical review and MRI/PET-CT for 2 years, then 6-monthly for 3 years) are provided to the patient's home oncology team via GAF Healthcare's care coordination platform.